Drug updated on 4/18/2024
| Dosage Form | Capsule (oral; 2.5 mg, 5 mg, 10 mg, 15 mg) |
| Drug Class | Cardiac myosin inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Summary
- Mavacamten (Camzyos) is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM), improving functional capacity and symptoms.
- Five studies were reviewed, all consistently reporting that mavacamten significantly improved at least one NYHA functional class in patients with HCM, indicating its efficacy.
- Mavacamten also showed a significant reduction in Septal Reduction Therapy rates across studies, suggesting its potential to decrease the need for further invasive therapy.
- Safety data revealed a slight increase in adverse events with mavacamten use; however, these were not statistically significant for severe adverse events when compared to placebo. Common side effects included atrial fibrillation and decreased left ventricular ejection fraction.
- Studies included patients of Caucasian and Chinese ethnicity, primarily aged 56 to 57.9 years old. While effective in obstructive HCM cases, more research is suggested on non-obstructive HCM patient benefits.
- Compared mainly against placebos rather than other specific treatments for HCM within the studies reviewed; mavacamten presents itself as a disease-specific option due to its mechanism as a cardiac myosin inhibitor targeting the underlying pathology of HCM - offering an innovative approach towards managing this condition.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Camzyos (mavacamten) Prescribing Information. | 2022 | Bristol Myers Squibb Brisbane, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. | 2024 | Heart failure reviews |
| Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: A systematic review and meta-analysis. | 2023 | Future Science OA |
| Efficacy and safety of mavacamten in the treatment of hypertrophic cardiomyopathy: A systematic review. | 2023 | Heart, Lung & Circulation |
| Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized clinical trials. | 2023 | The Egyptian Heart Journal |
| Mavacamten treatment for hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized controlled trials. | 2023 | Current Problems in Cardiology |